logo
New Insurity Survey Identifies Top Digital Features Policyholders Want and Key Areas for Improving Policyholder Engagement

New Insurity Survey Identifies Top Digital Features Policyholders Want and Key Areas for Improving Policyholder Engagement

Business Wire28-05-2025

HARTFORD, Conn.--(BUSINESS WIRE)-- Insurity, a leading provider of cloud-based software for insurance carriers, brokers, and MGAs, released new insights from its 2025 Digital Experience Index, which evaluates consumer satisfaction with digital interactions across the P&C insurance experience. The survey found that policyholders place increased value on three core digital services: streamlined billing and payments, immediate access to policy documents, and the ability to file and track claims online. For insurers aiming to boost retention and satisfaction, optimizing these essential touchpoints for simplicity, speed, and reliability should be a strategic priority.
While policyholders value digital convenience, the survey also identified several areas where insurers are falling short. Features such as 24/7 customer support and real-time claim status updates were among the lowest rated in terms of usefulness, suggesting that these critical service capabilities are not meeting expectations. When asked what would improve their experience, consumers cited more self-service tools, streamlined claims-filing processes, and better mobile app design, indicating an apparent demand for more intuitive, responsive digital touchpoints.
For insurers, these findings reinforce the need to align digital strategy with evolving customer expectations. Enhancing usability is no longer optional, particularly in high-impact areas like claims. In fact, the Digital Experience Index found that one in five consumers have avoided filing a claim due to frustrating processes, highlighting how poor digital experiences can directly undermine customer trust and long-term retention. Insurers must invest in solutions that remove complexity and deliver consistent, seamless interactions across the policyholder journey to stay competitive.
"Digital ease and speed are now essential for the insurance experience," said Sylvester Mathis, Chief Insurance and Chief Revenue Officer at Insurity. "The data underscores a crucial insight: policyholders increasingly demand seamless and empowering digital interactions that remove barriers and provide immediate solutions. Insurers that fail to prioritize user-centric platforms, especially during pivotal moments like filing a claim, risk losing individual transactions and eroding long-term trust and customer loyalty."
This survey was conducted online in April 2025, and more than 1,000 adult participants were randomly selected across the United States to ensure a representative sample. Respondents were asked a series of 19 questions, ranging from multiple-choice to scale-based, to gauge their opinions on their digital experience. Data analysis was performed to identify key patterns and insights.
To learn more about Insurity's 2025 Digital Experience Index and how policyholders feel about their digital experience with P&C insurers, please contact Elizabeth.Hutchinson@insurity.com.
About Insurity
Insurity is a leading provider of cloud-based software for insurance carriers, brokers, and MGAs. Insurity is trusted by 22 of the top 25 P&C carriers and 7 of the top 10 MGAs in the US and has over 400 cloud-based deployments. Through its best-in-class digital platform, unrivaled industry experience, and the industry's most robust analytics offerings, Insurity is uniquely positioned to deliver exceptional value, empowering customers to focus on their core businesses, optimize their operations, and provide superior policyholder experiences. Insurity is a portfolio company of GI Partners and TA Associates. For more information, visit www.insurity.com.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio
Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio

Yahoo

time34 minutes ago

  • Yahoo

Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio

SWEDESBORO, N.J., June 05, 2025--(BUSINESS WIRE)--Wedgewood Pharmacy today announced the availability of a GS-441524 formula, a compounded oral antiviral formulation now part of its feline infectious peritonitis (FIP) treatment capabilities. With this addition, veterinarians can now prescribe both GS-441524 and Molnupiravir for their patients, two of the most requested compounded antivirals for FIP, through a single trusted source backed by pharmacist support and FDA-registered ingredient sourcing. GS-441524 can be compounded as a 50mg/ml flavored oral oil suspension in multiple sizes, to improve compliance and ease of administration. The addition complements Wedgewood's Molnupiravir formulations, giving veterinarians access to two antivirals with distinct mechanisms of action. "FIP is one of the toughest diagnoses we face, not just clinically, but emotionally too," said Dr. Rae Hutchins, Chief Veterinary Officer at Wedgewood. "For a long time, vets had to deal with inconsistent access and quality when it came to GS-441524. Now, by offering both GS-441524 and Molnupiravir from one trusted, pharmacist-supported source, we're making it easier for veterinarians to focus on what matters most, giving their patients the best possible chance." "Having access to both GS-441524 and Molnupiravir compounded formulations through Wedgewood not only widens access to affordable FIP treatment across the US, but it also gives veterinarians the ability to easily choose and adapt treatment to best suit the needs of their patients and clients," said Nicole Jacque, co-founder of FIP Global Cats. "Having pharmacists who understand the urgency and complexity of these cases partnering with veterinarians is key to ensuring the best treatment outcomes for cats with FIP." Until recently, many veterinarians relied on fragmented or unregulated sources for GS-441524, making it difficult to ensure consistency and continuity of care. The introduction of this option through Wedgewood reflects a direct response to those challenges, providing prescribers with a trusted, quality-assured formulation from a pharmacy they can count on. The launch of GS-441524 builds on Wedgewood's long-standing role in supporting veterinarians with customized treatment solutions for complex cases. As part of its commitment to responsible compounding, the pharmacy emphasizes that its GS-441524 formulation is not approved by the FDA, has not been studied in clinical trials, and Wedgewood makes no claims of efficacy or safety. Independent third-party studies related to GS-441524 are available for veterinary reference through Wedgewood's FIP Resource Center. To learn more about GS-441524 and access educational resources, visit About WedgewoodWedgewood is the nation's largest and most trusted provider of compounded veterinary medications. Its next-generation home delivery platform, Blue Rabbit, streamlines patient care and marks a significant evolution in online pharmacy services. Together, Blue Rabbit and Wedgewood serve more than 70,000 veterinary professionals and more than one million animals annually. For more information visit About FIP Global Cats FIP Global CATS® (Community, Advocacy, Treatment, Support) is a leading organization in the fight against feline infectious peritonitis (FIP). Uniting veterinarians, researchers, and pet owners, it provides crucial support to those facing an FIP diagnosis. The organization is committed to empowering pet parents, advocating for safe, effective and affordable legal treatments, and advancing FIP research. For more information, please visit View source version on Contacts Jennifer Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio
Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio

Business Wire

time37 minutes ago

  • Business Wire

Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio

SWEDESBORO, N.J.--(BUSINESS WIRE)--Wedgewood Pharmacy today announced the availability of a GS-441524 formula, a compounded oral antiviral formulation now part of its feline infectious peritonitis (FIP) treatment capabilities. With this addition, veterinarians can now prescribe both GS-441524 and Molnupiravir for their patients, two of the most requested compounded antivirals for FIP, through a single trusted source backed by pharmacist support and FDA-registered ingredient sourcing. "Having access to both GS-441524 and Molnupiravir compounded formulations through Wedgewood not only widens access to affordable FIP treatment across the US, but it also gives veterinarians the ability to easily choose and adapt treatment." Share GS-441524 can be compounded as a 50mg/ml flavored oral oil suspension in multiple sizes, to improve compliance and ease of administration. The addition complements Wedgewood's Molnupiravir formulations, giving veterinarians access to two antivirals with distinct mechanisms of action. 'FIP is one of the toughest diagnoses we face, not just clinically, but emotionally too,' said Dr. Rae Hutchins, Chief Veterinary Officer at Wedgewood. 'For a long time, vets had to deal with inconsistent access and quality when it came to GS-441524. Now, by offering both GS-441524 and Molnupiravir from one trusted, pharmacist-supported source, we're making it easier for veterinarians to focus on what matters most, giving their patients the best possible chance.' "Having access to both GS-441524 and Molnupiravir compounded formulations through Wedgewood not only widens access to affordable FIP treatment across the US, but it also gives veterinarians the ability to easily choose and adapt treatment to best suit the needs of their patients and clients,' said Nicole Jacque, co-founder of FIP Global Cats. 'Having pharmacists who understand the urgency and complexity of these cases partnering with veterinarians is key to ensuring the best treatment outcomes for cats with FIP.' Until recently, many veterinarians relied on fragmented or unregulated sources for GS-441524, making it difficult to ensure consistency and continuity of care. The introduction of this option through Wedgewood reflects a direct response to those challenges, providing prescribers with a trusted, quality-assured formulation from a pharmacy they can count on. The launch of GS-441524 builds on Wedgewood's long-standing role in supporting veterinarians with customized treatment solutions for complex cases. As part of its commitment to responsible compounding, the pharmacy emphasizes that its GS-441524 formulation is not approved by the FDA, has not been studied in clinical trials, and Wedgewood makes no claims of efficacy or safety. Independent third-party studies related to GS-441524 are available for veterinary reference through Wedgewood's FIP Resource Center. To learn more about GS-441524 and access educational resources, visit About Wedgewood Wedgewood is the nation's largest and most trusted provider of compounded veterinary medications. Its next-generation home delivery platform, Blue Rabbit, streamlines patient care and marks a significant evolution in online pharmacy services. Together, Blue Rabbit and Wedgewood serve more than 70,000 veterinary professionals and more than one million animals annually. For more information visit About FIP Global Cats FIP Global CATS® (Community, Advocacy, Treatment, Support) is a leading organization in the fight against feline infectious peritonitis (FIP). Uniting veterinarians, researchers, and pet owners, it provides crucial support to those facing an FIP diagnosis. The organization is committed to empowering pet parents, advocating for safe, effective and affordable legal treatments, and advancing FIP research. For more information, please visit

2Modern Welcomes Nicole Andrew as Chief Marketing Officer
2Modern Welcomes Nicole Andrew as Chief Marketing Officer

Yahoo

timean hour ago

  • Yahoo

2Modern Welcomes Nicole Andrew as Chief Marketing Officer

MILL VALLEY, Calif., June 05, 2025--(BUSINESS WIRE)--2Modern, a leading retailer for modern design since 2003, proudly announces the appointment of Nicole Andrew as Chief Marketing Officer (CMO). Reporting directly to CEO Greg Finney, Andrew joins the executive leadership team with 17 years in luxury retail & e-commerce marketing and merchandising, including a deep expertise in the design industry. As CMO, Andrew will lead all aspects of marketing, including brand strategy, performance marketing, creative, partnerships, and customer acquisition and retention. Her focus will be on accelerating growth and enhancing the customer experience, marking a pivotal moment as 2Modern enters a new chapter of expansion in the premium design space. Andrew most recently served as Chief Marketing Officer at Perigold, where she played a key role in shaping the brand's identity and driving significant growth over her eight year tenure. Her leadership, strategic vision, and digital expertise helped position Perigold as a standout in luxury e-commerce. "We're thrilled to welcome Nicole to the 2Modern leadership team," said CEO Greg Finney. "Her track record of building strong brands and her deep passion for design make her a perfect fit for our next stage of growth." "I'm incredibly excited to join 2Modern at such a dynamic time," said Andrew. "In just a few weeks, we've already begun reimagining the customer journey, strengthening storytelling across channels, and identifying new opportunities for growth. I've long admired 2Modern's commitment to authentic, elevated design and look forward to building on that legacy." About 2Modern 2Modern is a leading retailer of modern furniture, lighting, and home accessories, dedicated to bringing timeless design into contemporary living spaces. Established in 2003, 2Modern is focused on partnering with iconic and emerging global design brands to inspire customers and elevate interiors through thoughtful, forward-thinking design. For more information, please visit and follow @2modern on Instagram, Facebook, and Pinterest. View source version on Contacts press@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store